In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
ABSTRACTCarbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. represent major threats and have few approved therapeutic options. Non-fermenting Gram-negative isolates were collected from hospitalized inpatients from 49 sites in 6 European countries between 01 January 2020 and 31 Decemb...
Main Authors: | Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D. Perry, Mathias W. Pletz, Stefania Stefani, Ian Morrissey, Christopher Longshaw |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2024-04-01
|
Series: | Microbiology Spectrum |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/spectrum.03836-23 |
Similar Items
-
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations
by: Anne Santerre Henriksen, et al.
Published: (2024-08-01) -
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
by: François Barbier, et al.
Published: (2023-07-01) -
In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01) -
In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing <i>Klebsiella pneumoniae</i>: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
by: Snehal Palwe, et al.
Published: (2021-10-01) -
Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection
by: Tarski I, et al.
Published: (2024-11-01)